White matter microstructural differences in children and genetic risk for multiple sclerosis: A population-based study
Year: 2021
Type: article
Study design: Observational Study
Abstract: Background: MS patients show abnormalities in white matter (WM) on brain imaging, with heterogeneity in the location of WM lesions. The “pothole” method can be applied to diffusion-weighted images to identify spatially distinct clusters of divergent brain WM microstructure. Objective: To investigate the association between genetic risk for MS and spatially independent clusters of decreased or increased fractional anisotropy (FA) in the brain. In addition, we studied sex- and age-related differences. Methods: 3 Tesla diffusion tensor imaging (DTI) data were collected in 8- to 12-year-old children from a population-based study. Global and tract-based potholes (lower FA clusters) and molehills (higher FA clusters) were quantified in 3047 participants with usable DTI data. A polygenic risk score (PRS) for MS was calculated in genotyped individuals ( n = 1087) and linear regression analyses assessed the relationship between the PRS and the number of potholes and molehills, correcting for multiple testing using the False Discovery Rate. Results: The number of molehills increased with age, potholes decreased with age, and fewer potholes were observed in girls during typical development. The MS-PRS was positively associated with the number of molehills (β = 0.9, SE = 0.29, p = 0.002). Molehills were found more often in the corpus callosum (β = 0.3, SE = 0.09, p = 0.0003). Conclusion: Genetic risk for MS is associated with spatially distinct clusters of increased FA during childhood brain development.
Source: Multiple Sclerosis Journal
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,000
Funders: U.S. Department of Defense, Foundation for the National Institutes of Health, Alzheimer's Association, Bristol-Myers Squibb, Alzheimer's Drug Discovery Foundation, Eli Lilly and Company, Pfizer, Roche, Biogen, University of Southern California, Meso Scale Diagnostics, Alzheimer's Disease Neuroimaging Initiative, Familjen Erling-Perssons Stiftelse, BioClinica, Novartis Pharmaceuticals Corporation, Northern California Institute for Research and Education, Stiftelsen för Gamla Tjänarinnor, European Federation of Pharmaceutical Industries and Associations, National Institute for Health and Care Research, European Commission, National Research Foundation, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, ZonMw, Stichting MS Research, Eusko Jaurlaritza, Fonds Wetenschappelijk Onderzoek, Eisai, Hjärnfonden, Vetenskapsrådet, Universiteit Antwerpen, University College London Hospitals NHS Foundation Trust, Innovative Medicines Initiative, Servier, Vlaamse regering, H. Lundbeck A/S, IXICO, UK Dementia Research Institute, Olav Thon Stiftelsen, National Institutes of Health, Genentech, Canadian Institutes of Health Research, National Institute on Aging, National Institute of Biomedical Imaging and Bioengineering, H2020 European Research Council
Awards: G1010232553, G1012222616, G1057200632, G1551449788, G1588116593, G160417252, G201353144, G2074436950, G2308068485, G237833635, G2384069237, G2423387114, G2522063444, G2567931567, G2835601961, G292763017, G29951154, G3146424788, G3207356259, G3870774570, Macrophage migration inhibitory factor and neuroinflammation in early Alzheimer’s Disease, G393177772, G3966393351, G4119534169, G4196769506, Data-driven models for Progression Of Neurological Disease, G434337789, G4401988282, G4475667458, Physical and chemical properties of clusters in a molecular beam and deposited in a matrix or on a surface, G4860885537, European Prevention of Alzheimer’s Dementia Consortium, G4896876283, Flächensparen beim Verkehr, G5332654608, EFFECTS OF TRAUMATIC BRAIN INJURY (TBI) AND POST TRAUMATIC STRESS DISORDER (PTSD) ON ALZHEIMER'S DISEASE (AD) IN VETERANS USING IMAGING AND BIOMARKERS IN THE AD NEUROIMAGING INITIATIVE (ADNI)", G5702163051, Alzheimer's Disease Neuroimaging Initiative, G6020134442, G6114654967, G6237904309, G6382720711, Multi-omics Interdisciplinary Research Integration to Address DEmentia diagnosis, G691317373, Pathways to Alzheimer's disease, G6991793898, G714280318, G7511831505, European Medical Information Framework, What determines amyloid beta aggregation and toxicity in Alzheimer’s disease?, G9000074849, G9000122335, G920654007
OpenAlex ID: W3193036633
